Castle Biosciences director Daniel Bradbury filed a Form 4 on November 19, 2026, disclosing a gift of 5,985 shares of common stock to a charitable donor advised fund on November 17, 2026, and a concurrent transfer of shares to a family trust.

Key Highlights

  • Gift transaction: Daniel Bradbury disposed of 5,985 shares of Castle Biosciences common stock via a bona fide gift to a charitable donor advised fund for no consideration on November 17, 2026.
  • No retained interest: According to the filing, the reporting person "retains no voting, investment, or pecuniary interest in the gifted shares."
  • Family trust transfer: On the same date, 22,340 shares were transferred from Bradbury's direct holdings to The Bradbury Family Trust.
  • Post-transaction indirect holdings: Following the reported transactions, Bradbury beneficially owns 29,646 shares indirectly through The Bradbury Family Trust.
  • Trustee relationship: The Bradbury Family Trust is held by the trust of which Daniel Bradbury and Annette Bradbury are both trustees and beneficiaries.
  • Issuer: Castle Biosciences Inc., listed on NASDAQ:CSTL.

Bradbury's November 2026 Gift and Trust Transfer at Castle Biosciences

Castle Biosciences director Daniel Bradbury reported two transactions in a Form 4 filed November 19, 2026, both dated November 17, 2026. The first was the disposal of 5,985 shares of Castle Biosciences common stock through a gift to a charitable donor advised fund. The filing states the transaction was a "bona fide gift by the Reporting Person, for no consideration," and specifies that Bradbury retains no voting, investment, or pecuniary interest in those shares.

The second transaction reported was the transfer of 22,340 shares from Bradbury's direct holdings to The Bradbury Family Trust. The filing notes that Bradbury and Annette Bradbury serve as both trustees and beneficiaries of that trust. Following both transactions, Bradbury's reported beneficial ownership stands at 29,646 shares held indirectly through The Bradbury Family Trust. The filing does not report any directly held shares remaining after the transactions.

Both transactions carried a price of $0, consistent with the gift and intra-family trust transfer nature described in the filing's footnotes. The Form 4 was signed by Frank Stokes as attorney-in-fact on November 19, 2026, and filed on the same date with the U.S. Securities and Exchange Commission under Section 16(a) of the Securities Exchange Act of 1934.

What Was Disclosed

Director Daniel Bradbury disclosed the gift of 5,985 Castle Biosciences shares to a charitable donor advised fund for no consideration, and the transfer of 22,340 shares to The Bradbury Family Trust, leaving him with 29,646 shares beneficially owned indirectly through that trust.